UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-09, Vol.19 (5), p.691-697

2013

Volltextzugriff (PDF)

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-01, Vol.21 (1), p.34-40

2015

Volltextzugriff (PDF)

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-11, Vol.17 (6), p.854-859

2011

Volltextzugriff (PDF)

Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-09, Vol.22 (5), p.e445-e449

2016

Volltextzugriff (PDF)

Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-09, Vol.21 (5), p.e436-e439

2015

Volltextzugriff (PDF)

Recombinant factor concentrates may increase inhibitor development: a single centre cohort study

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-07, Vol.17 (4), p.625-629

2011

Volltextzugriff (PDF)

Recombinant activated factor VII (NovoSeven™): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding

Vox sanguinis, 2004-07, Vol.87 (1), p.34-40

2004

Volltextzugriff (PDF)

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Thrombosis and haemostasis, 2017, Vol.117 (2), p.252-261

2017

Volltextzugriff (PDF)

PB0627 Management of Invasive Procedures in Patients with Hemophilia A Receiving Emicizumab Prophylaxis: Real-World Data from a National Hemophilia Treatment Center

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7, p.101203, Article 101203

2023

Volltextzugriff (PDF)

Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-09, Vol.22 (5), p.e445-e449

2016

Volltextzugriff (PDF)

Adam et l'Astragale

2009

Volltextzugriff (PDF)

The Clinical Findings in Young Adults with Acute Scrotal Pain

The American journal of emergency medicine, 2016-10, Vol.34 (10), p.1931-1933

2016

Volltextzugriff (PDF)

Enoxaparin can be Used Safely in Patients with Severe Thrombocytopenia due to Intensive Chemotherapy Regimens

Leukemia & lymphoma, 2004-07, Vol.45 (7), p.1407-1411

2004

Volltextzugriff (PDF)

Isolated Torsion of Accessory Fallopian Tube in a Young Adolescent

Journal of pediatric & adolescent gynecology, 2016-08, Vol.29 (4), p.e57-e58

2016

Volltextzugriff (PDF)

Fatal pulmonary artery thrombosis in a patient with Behçet's disease, activated protein C resistance and hyperhomocystinemia

Blood coagulation & fibrinolysis, 2000-07, Vol.11 (5), p.421-423

2000

Volltextzugriff (PDF)

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A: BIOEQUIVALENCE BETWEEN N8 AND ADVATE

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-11, Vol.17 (6), p.854-859

2011

Volltextzugriff (PDF)

Recombinant factor concentrates may increase inhibitor development: a single centre cohort study: EARLY EXPOSURE TO RECOMBINANT FACTOR INCREASE INHIBITOR DEVELOPMENT

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-07, Vol.17 (4), p.625-629

2011

Volltextzugriff (PDF)

Thrombotic thrombocytopenic purpura--new insights in the pathogenesis, diagnosis and modern therapy

הרפואה, 2001-07, Vol.140 (7), p.653

2001

Volltextzugriff (PDF)

Upper extremity deep vein thrombosis

הרפואה, 1999-02, Vol.136 (3), p.224

1999

Volltextzugriff (PDF)

A new mutation in the prothrombin gene (G20210A) and the risk for venous and arterial thromboembolism

הרפואה, 2000-07, Vol.139 (1-2), p.51

2000

Volltextzugriff (PDF)

Atrial septal aneurysm as a possible cause of cardiac embolism

הרפואה, 1998-12, Vol.135 (11), p.534

1998

Volltextzugriff (PDF)

Iudaea / Idumaea: 2649-3324: A multi-lingual corpus of the inscriptions from Alexander to Muhammad

Walter Ameling, Hannah M. Cotton, Werner Eck, Avner Ecker, Benjamin Isaac, Alla Kushnir-Stein, Haggai Misgav, Jonathan Price, Peter Weiß, Ada Yardeni, Walter Ameling, Hannah M. Cotton, Werner Eck, Avner Ecker, Benjamin Isaac, Alla Kushnir-Stein, Haggai Misgav, Jonathan Price, Peter Weiß, Ada Yardeni

2018

Volltextzugriff (PDF)

Caesarea and the Middle Coast: 1121-2160

Walter Ameling, Hannah M. Cotton, Werner Eck, Benjamin Isaac, Alla Kushnir-Stein, Haggai Misgav, Jonathan Price, Ada Yardeni, Walter Ameling, Hannah M. Cotton, Werner Eck, Benjamin Isaac, Alla Kushnir-Stein, Haggai Misgav, Jonathan Price, Ada Yardeni

2011

Volltextzugriff (PDF)

Jerusalem: 705-1120

Hannah M. Cotton, Leah Di Segni, Werner Eck, Benjamin Isaac, Alla Kushnir-Stein, Haggai Misgav, Jonathan J. Price, Ada Yardeni, Hannah M. Cotton, Leah Di Segni, Werner Eck, Benjamin Isaac, Alla Kushnir-Stein, Haggai Misgav, Jonathan J. Price, Ada Yardeni

2012

Volltextzugriff (PDF)

Jerusalem: 1-704

Hannah M. Cotton, Leah Di Segni, Werner Eck, Benjamin Isaac, Alla Kushnir-Stein, Haggai Misgav, Jonathan Price, Israel Roll, Ada Yardeni, Hannah M. Cotton, Leah Di Segni, Werner Eck, Benjamin Isaac, Alla Kushnir-Stein, Haggai Misgav, Jonathan Price, Israel Roll, Ada Yardeni

2010

Volltextzugriff (PDF)

1 – 25 von 466

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(457)

Publikationsform

Buchkapitel
(406)
Artikel
(38)
Bücher
(21)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

Recombinant factor concentrates may increase inhibitor development: a single centre cohort study

Recombinant activated factor VII (NovoSeven™): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

PB0627 Management of Invasive Procedures in Patients with Hemophilia A Receiving Emicizumab Prophylaxis: Real-World Data from a National Hemophilia Treatment Center

Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Adam et l'Astragale

The Clinical Findings in Young Adults with Acute Scrotal Pain

Enoxaparin can be Used Safely in Patients with Severe Thrombocytopenia due to Intensive Chemotherapy Regimens

Isolated Torsion of Accessory Fallopian Tube in a Young Adolescent

Fatal pulmonary artery thrombosis in a patient with Behçet's disease, activated protein C resistance and hyperhomocystinemia

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A: BIOEQUIVALENCE BETWEEN N8 AND ADVATE

Recombinant factor concentrates may increase inhibitor development: a single centre cohort study: EARLY EXPOSURE TO RECOMBINANT FACTOR INCREASE INHIBITOR DEVELOPMENT

Thrombotic thrombocytopenic purpura--new insights in the pathogenesis, diagnosis and modern therapy

Upper extremity deep vein thrombosis

A new mutation in the prothrombin gene (G20210A) and the risk for venous and arterial thromboembolism

Atrial septal aneurysm as a possible cause of cardiac embolism

Iudaea / Idumaea: 2649-3324: A multi-lingual corpus of the inscriptions from Alexander to Muhammad

Caesarea and the Middle Coast: 1121-2160

Jerusalem: 705-1120

Jerusalem: 1-704

Suchergebnisse filtern